Developer docs
API playgroundTry for free, no card

Search company profiles

MedPacto

Full company profile

uuid0005zlp

Namestring
MedPacto
Legal namestring
주식회사 메드팩토 (MedPacto, Inc.)
Websiteurl
medpacto.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

MedPacto is a clinical-stage biotechnology company founded in 2013 and headquartered in Seocho-gu, Seoul, South Korea, that develops biomarker-guided precision oncology therapeutics through a TGF-β signaling inhibition platform. Its lead asset, Vactosertib (TEW-7197), is an oral selective TGF-β receptor I (ALK5) kinase inhibitor designed to neutralize tumor microenvironment immunosuppression, enhance immune-cell tumor killing, suppress metastasis, and break down stromal barriers, enabling combination with immunotherapies, targeted therapies, and chemotherapies across multiple solid tumor indications. The pipeline includes three additional first-in-class candidates: MP010, a bifunctional TME-targeted trap combining TGF-β neutralization with EDB-FN tumor targeting; MP2021, an Fc-fusion protein targeting TM4SF19 for osteoporosis and inflammatory arthritis; and MA-B2/MO-B2, a BAG2-targeting antibody therapeutic with companion diagnostic. The company pursues co-development with global pharmaceutical partners — including MSD for Phase 3 Vactosertib + Keytruda in metastatic colorectal cancer, AstraZeneca for Imfinzi combinations in bladder cancer and NSCLC, and Samsung Biologics for antibody manufacturing — alongside investigator-initiated trials at Fred Hutchinson Cancer Research Center, Weill Cornell, and the Case Comprehensive Cancer Center. FDA has granted Vactosertib Orphan Drug Designations in osteosarcoma, pancreatic cancer and gastric cancer, plus Fast Track and Rare Pediatric Disease Designations for metastatic osteosarcoma; the EMA has granted Orphan Medicinal Product Designation for osteosarcoma.

MedPacto is pre-commercial, generating no product revenue. Its revenue model anticipates future income from product sales following regulatory approval, supplemented by upfront payments, milestone payments, and royalties from technology licensing and co-development agreements with global pharmaceutical companies. The company has secured approximately 74.1 billion KRW (~$55M) in late 2023 capital raise funding, with cash reserves of approximately 480 billion KRW as of 1H25, plus prior Series A/B funding of $16M, Series C funding of $25M in June 2019, a 100 billion KRW investment in December 2020, and $7.5M in funding for its US subsidiary Celloram in August 2020. The company listed on KOSDAQ (ticker 235980) in December 2019 at an IPO price of 40,000 KRW per share, and operates with 51–100 employees across headquarters in Seoul and its wholly-owned US subsidiary MedPacto Therapeutics Inc. (established 2021), alongside a 24%-owned US subsidiary Celloram Inc. (founded 2018).

Short descriptiontext

MedPacto is a clinical-stage Korean biotechnology company developing biomarker-guided precision oncology therapeutics, led by the TGF-β receptor I inhibitor Vactosertib now in a Phase 3 trial with MSD for metastatic colorectal cancer, alongside three additional first-in-class pipeline candidates spanning solid tumors, bone disease and companion diagnostics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, TGF-beta inhibitors, oncology drug development, biomarker-based precision medicine, cancer immunotherapy combinations
Industry5 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Biopharmaceuticals (Oncology)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeLicensing Royalties
Description

MedPacto is a pre-commercial clinical-stage biopharmaceutical company. Revenue will be generated through product sales following regulatory approval, as well as upfront payments, milestone payments, and royalties from technology licensing and co-development partnerships with global pharmaceutical companies.

medpacto.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Vactosertib (백토서팁)
Description

TGF-β receptor I inhibitor for cancer treatment - the company's lead pipeline candidate

medpacto.com
+3 more records
Core offering1 text field

MedPacto is a clinical-stage biopharmaceutical company developing biomarker-based first-in-class therapeutics centered on TGF-β signaling inhibition for cancer and inflammatory diseases. Its lead asset, oral Vactosertib, is being advanced in monotherapy and combination regimens across multiple cancer types, supplemented by pipeline candidates MP010, MP2021, MA-B2, and MO-B2 companion diagnostic. The company generates near-term revenue through licensing, co-development milestones, and royalties, and plans future commercialization via partnerships with global pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 75% two-year overall survival in recurrent pulmonary metastatic osteosarcoma patients vs 40% historical controls (Phase IIb OST-HER2 immunotherapy trial by OS Therapies)
+3 more records
Product overview1 text field

MedPacto is a biomarker-based First-in-Class drug development company focused on innovative cancer therapeutics. The core product is Vactosertib, an oral TGF-β receptor I inhibitor, alongside next-generation pipeline candidates MP010 (TME-targeting bifunctional fusion protein), MP2021 (TM4SF19 inhibitor for bone diseases), MA-B2 (BAG2-targeting antibody therapeutic), and MO-B2 (companion diagnostic kit for breast cancer). The company develops treatments through genome-based approaches to overcome limitations of existing anticancer drugs and implements precision medicine through biomarker-based drug development.

Product and service5 records
1Vactosertib (TEW-7197) (백토서팁)
CategoryCore Pipeline Product (TGF-β Inhibitor)
Description

Oral, potent, and selective TGF-β Receptor I (ALK5) kinase inhibitor developed by MedPacto for the treatment of solid tumors including osteosarcoma, metastatic colorectal cancer (MSS), NSCLC, gastric cancer, pancreatic cancer, multiple myeloma, and desmoid tumors. It can be combined with immunotherapies, targeted therapies, and chemotherapies. Currently in Phase 2b/3 development with co-development partner Merck/MSD.

2MP010
CategoryPipeline Product (TME-Targeted Bifunctional Fusion Protein)
Description

Next-generation bifunctional fusion protein platform drug targeting the tumor microenvironment (TME). Combines a TGF-β trap with EDB-FN tumor-targeting to break down extracellular matrix barriers and activate immune cells locally against solid tumors. Indicated for solid tumor applications including pancreatic cancer.

3MP2021
CategoryPipeline Product (Bone & Inflammatory Disease Therapeutic)
Description

First-in-class Fc-fusion protein targeting TM4SF19, a novel tetraspanin membrane protein, for the treatment of osteoporosis, inflammatory arthritis, bone metastatic disease, and muscle wasting conditions. Acts via dual mechanism on bone loss and inflammation.

4MA-B2
CategoryPipeline Product (BAG2-Targeting Antibody Therapeutic)
Description

First-in-class antibody therapeutic targeting BAG2 protein to inhibit cathepsin B metastatic activity and block BAG2-mediated immunosuppression, activating the immune system against cancer, particularly for metastatic and recurrent disease settings.

5MO-B2
CategoryCompanion Diagnostic Product
Description

Companion diagnostic kit for the detection of BAG2 protein levels in serum using sandwich ELISA methodology. Used to predict breast cancer metastasis and recurrence, particularly for triple-negative breast cancer patients.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-12-14
Description

Global Phase 3 co-development agreement for Vactosertib + Keytruda (pembrolizumab) combination therapy in metastatic colorectal cancer. MSD provides Keytruda at no cost for the trial (approximately 35% of Phase 3 costs). First time a Korean biotech company entered Phase 3 co-development with MSD. Additional Phase 1b/2a trials ongoing in NSCLC and other indications.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-10-01
Description

Investigator-initiated clinical trial collaboration for NK cell therapy + Vactosertib combination in colorectal cancer and hematologic malignancies.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-04-14
Description

Contract manufacturing organization (CMO) agreement for antibody treatment development, leveraging Samsung Biologics' expertise in biopharmaceutical manufacturing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-05-26
Description

Clinical collaboration for Vactosertib + Keytruda (pembrolizumab) combination therapy in multiple cancer types including NSCLC and gastric cancer. Part of broader strategic partnership for combination therapy development.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-22
Description

Operating agreement establishing framework for clinical trial collaboration including NK cell therapy combinations with Vactosertib.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-07-24
Description

Clinical trial collaboration for Vactosertib + Imfinzi (durvalumab) combination therapy in bladder cancer (urothelial carcinoma) and NSCLC. Phase 1b/2a trials conducted in Korea with top-line data presented in 2024.

Strategic tierCoreTypeOthersAnnounced on2018-01-01
Description

U.S. subsidiary established by MedPacto (24% ownership) with co-founder John Letterio from Case Western Reserve. Raised $7.5M in 2020. Focused on autoimmune diseases, cancer vaccines, and inflammatory diseases. Pipeline includes CLM-022 inflammasome inhibitor and tolerogenic dendritic cell therapies.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US clinical-stage immuno-oncology biotech developing antibody-based therapeutics including combinations with checkpoint inhibitors. Comparable business model as a clinical-stage IO platform company pursuing combination strategies with PD-1/PD-L1 agents.

TypeDirect peer
Description

US clinical-stage biotech focused on TGF-β superfamily biology (latent TGF-β activation), with lead asset apitegromab in neuromuscular disease. Directly comparable as a TGF-β platform company advancing targeted therapeutics into Phase 3.

TypeEmerging player
Description

Global oncology company with broad immuno-oncology pipeline including checkpoint inhibitors used in combination trials. Comparable as a peer that validates the immuno-oncology combination strategy MedPacto is pursuing.

TypeDirect peer
Description

Korean clinical-stage biotechnology company developing immuno-oncology and immunology therapeutics with a comparable size, public KOSDAQ listing, and strategic overlap in cancer combination therapies. Direct overlap in Korean biotech peer set and former employer of MedPacto's new CEO.

TypeRegional player
Description

Korean pharmaceutical innovator with multiple oncology and immunology pipeline assets. Comparable as a Korean regional player with similar pipeline strategies targeting global partnerships and out-licensing opportunities.

TypeDirect peer
Description

French clinical-stage biopharmaceutical company focused on inflammatory and metabolic diseases, and current licensee of MedPacto's Celloram subsidiary's CLM-022 inflammasome inhibitor. Comparable as a clinical-stage partner with shared deal economics.

TypeRegional player
Description

Major Korean pharmaceutical company with growing oncology and innovative drug pipeline. Comparable as a domestic Korean partner with capacity to in-license or collaborate on MedPacto's pipeline assets in the Korean market.

8I-Mab Biopharma
TypeEmerging player
Description

Clinical-stage biotech developing immuno-oncology assets including bispecific antibodies and combinations. Comparable as an emerging player in the IO space pursuing global partnership opportunities with large pharma.

TypeEmerging player
Description

Chinese clinical-stage and commercial biotech with strong PD-1 combination pipeline. Comparable as an Asian emerging player developing IO combination therapies and pursuing global pharmaceutical partnerships.

TypeBroad incumbent
Description

Large pharmaceutical company that historically developed galunisertib, a competing TGF-β receptor I inhibitor in oncology. Comparable as a broad incumbent whose TGF-β clinical outcomes inform the validation and competitive context for MedPacto's Vactosertib.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MedPacto

Clinical-stage Biopharmaceuticals (Oncology)medpacto.com

MedPacto is a clinical-stage Korean biotechnology company developing biomarker-guided precision oncology therapeutics, led by the TGF-β receptor I inhibitor Vactosertib now in a Phase 3 trial with MSD for metastatic colorectal cancer, alongside three additional first-in-class pipeline candidates spanning solid tumors, bone disease and companion diagnostics.

What MedPacto does

MedPacto is a clinical-stage biotechnology company founded in 2013 and headquartered in Seocho-gu, Seoul, South Korea, that develops biomarker-guided precision oncology therapeutics through a TGF-β signaling inhibition platform. Its lead asset, Vactosertib (TEW-7197), is an oral selective TGF-β receptor I (ALK5) kinase inhibitor designed to neutralize tumor microenvironment immunosuppression, enhance immune-cell tumor killing, suppress metastasis, and break down stromal barriers, enabling combination with immunotherapies, targeted therapies, and chemotherapies across multiple solid tumor indications. The pipeline includes three additional first-in-class candidates: MP010, a bifunctional TME-targeted trap combining TGF-β neutralization with EDB-FN tumor targeting; MP2021, an Fc-fusion protein targeting TM4SF19 for osteoporosis and inflammatory arthritis; and MA-B2/MO-B2, a BAG2-targeting antibody therapeutic with companion diagnostic. The company pursues co-development with global pharmaceutical partners — including MSD for Phase 3 Vactosertib + Keytruda in metastatic colorectal cancer, AstraZeneca for Imfinzi combinations in bladder cancer and NSCLC, and Samsung Biologics for antibody manufacturing — alongside investigator-initiated trials at Fred Hutchinson Cancer Research Center, Weill Cornell, and the Case Comprehensive Cancer Center. FDA has granted Vactosertib Orphan Drug Designations in osteosarcoma, pancreatic cancer and gastric cancer, plus Fast Track and Rare Pediatric Disease Designations for metastatic osteosarcoma; the EMA has granted Orphan Medicinal Product Designation for osteosarcoma.

MedPacto is pre-commercial, generating no product revenue. Its revenue model anticipates future income from product sales following regulatory approval, supplemented by upfront payments, milestone payments, and royalties from technology licensing and co-development agreements with global pharmaceutical companies. The company has secured approximately 74.1 billion KRW (~$55M) in late 2023 capital raise funding, with cash reserves of approximately 480 billion KRW as of 1H25, plus prior Series A/B funding of $16M, Series C funding of $25M in June 2019, a 100 billion KRW investment in December 2020, and $7.5M in funding for its US subsidiary Celloram in August 2020. The company listed on KOSDAQ (ticker 235980) in December 2019 at an IPO price of 40,000 KRW per share, and operates with 51–100 employees across headquarters in Seoul and its wholly-owned US subsidiary MedPacto Therapeutics Inc. (established 2021), alongside a 24%-owned US subsidiary Celloram Inc. (founded 2018).

MedPacto firmographics

Firmographics
Name
MedPacto
Legal name
주식회사 메드팩토 (MedPacto, Inc.)
Website
https://medpacto.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
MedPacto is a clinical-stage Korean biotechnology company developing biomarker-guided precision oncology therapeutics, led by the TGF-β receptor I inhibitor Vactosertib now in a Phase 3 trial with MSD for metastatic colorectal cancer, alongside three additional first-in-class pipeline candidates spanning solid tumors, bone disease and companion diagnostics.
Ownership category
akta.pro rank

MedPacto industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals (Oncology)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Clinical-stage biopharmaceuticals
  • TGF-beta inhibitors
  • Oncology drug development
  • Biomarker-based precision medicine
  • Cancer immunotherapy combinations

Where MedPacto is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

MedPacto business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Drug Development and Commercialization: MedPacto is a pre-commercial clinical-stage biopharmaceutical company. Revenue will be generated through product sales following regulatory approval, as well as upfront payments, milestone payments, and royalties from technology licensing and co-development partnerships with global pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

MedPacto product offering

Product offering

Core offering

MedPacto is a clinical-stage biopharmaceutical company developing biomarker-based first-in-class therapeutics centered on TGF-β signaling inhibition for cancer and inflammatory diseases. Its lead asset, oral Vactosertib, is being advanced in monotherapy and combination regimens across multiple cancer types, supplemented by pipeline candidates MP010, MP2021, MA-B2, and MO-B2 companion diagnostic. The company generates near-term revenue through licensing, co-development milestones, and royalties, and plans future commercialization via partnerships with global pharmaceutical companies.

Product overview

MedPacto is a biomarker-based First-in-Class drug development company focused on innovative cancer therapeutics. The core product is Vactosertib, an oral TGF-β receptor I inhibitor, alongside next-generation pipeline candidates MP010 (TME-targeting bifunctional fusion protein), MP2021 (TM4SF19 inhibitor for bone diseases), MA-B2 (BAG2-targeting antibody therapeutic), and MO-B2 (companion diagnostic kit for breast cancer). The company develops treatments through genome-based approaches to overcome limitations of existing anticancer drugs and implements precision medicine through biomarker-based drug development.

Differentiator

Problem solved

Functional benefit

Brands

  • Vactosertib (백토서팁): TGF-β receptor I inhibitor for cancer treatment - the company's lead pipeline candidate
  • MP010
  • MP2021
  • MA-B2/MO-B2

Products and services

  • Vactosertib (TEW-7197) (백토서팁) Oral, potent, and selective TGF-β Receptor I (ALK5) kinase inhibitor developed by MedPacto for the treatment of solid tumors including osteosarcoma, metastatic colorectal cancer (MSS), NSCLC, gastric cancer, pancreatic cancer, multiple myeloma, and desmoid tumors. It can be combined with immunotherapies, targeted therapies, and chemotherapies. Currently in Phase 2b/3 development with co-development partner Merck/MSD.
  • MP010 Next-generation bifunctional fusion protein platform drug targeting the tumor microenvironment (TME). Combines a TGF-β trap with EDB-FN tumor-targeting to break down extracellular matrix barriers and activate immune cells locally against solid tumors. Indicated for solid tumor applications including pancreatic cancer.
  • MP2021 First-in-class Fc-fusion protein targeting TM4SF19, a novel tetraspanin membrane protein, for the treatment of osteoporosis, inflammatory arthritis, bone metastatic disease, and muscle wasting conditions. Acts via dual mechanism on bone loss and inflammation.
  • MA-B2 First-in-class antibody therapeutic targeting BAG2 protein to inhibit cathepsin B metastatic activity and block BAG2-mediated immunosuppression, activating the immune system against cancer, particularly for metastatic and recurrent disease settings.
  • MO-B2 Companion diagnostic kit for the detection of BAG2 protein levels in serum using sandwich ELISA methodology. Used to predict breast cancer metastasis and recurrence, particularly for triple-negative breast cancer patients.

Quantifiable outcome

  • 75% two-year overall survival in recurrent pulmonary metastatic osteosarcoma patients vs 40% historical controls (Phase IIb OST-HER2 immunotherapy trial by OS Therapies)
  • +3 more outcomes

Companies that use MedPacto

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

MedPacto technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

MedPacto partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Merck (MSD)coreStrategic or Co-development Partner · 14 December 2021Global Phase 3 co-development agreement for Vactosertib + Keytruda (pembrolizumab) combination therapy in metastatic colorectal cancer. MSD provides Keytruda at no cost for the trial (approximately 35% of Phase 3 costs). First time a Korean biotech company entered Phase 3 co-development with MSD. Additional Phase 1b/2a trials ongoing in NSCLC and other indications.
  • Fred Hutchinson Cancer Research CenterminorStrategic or Co-development Partner · 1 October 2021Investigator-initiated clinical trial collaboration for NK cell therapy + Vactosertib combination in colorectal cancer and hematologic malignancies.
  • Samsung BiologicsminorStrategic or Co-development Partner · 14 April 2021Contract manufacturing organization (CMO) agreement for antibody treatment development, leveraging Samsung Biologics' expertise in biopharmaceutical manufacturing.
  • Merck (MSD) - Keytruda combinationcoreStrategic or Co-development Partner · 26 May 2020Clinical collaboration for Vactosertib + Keytruda (pembrolizumab) combination therapy in multiple cancer types including NSCLC and gastric cancer. Part of broader strategic partnership for combination therapy development.
  • Fred Hutchinson Cancer Research Center - operating agreementminorStrategic or Co-development Partner · 22 January 2020Operating agreement establishing framework for clinical trial collaboration including NK cell therapy combinations with Vactosertib.
  • AstraZeneca - Imfinzi combinationcoreStrategic or Co-development Partner · 24 July 2018Clinical trial collaboration for Vactosertib + Imfinzi (durvalumab) combination therapy in bladder cancer (urothelial carcinoma) and NSCLC. Phase 1b/2a trials conducted in Korea with top-line data presented in 2024.
  • Celloram (U.S. subsidiary)coreOthers · 1 January 2018U.S. subsidiary established by MedPacto (24% ownership) with co-founder John Letterio from Case Western Reserve. Raised $7.5M in 2020. Focused on autoimmune diseases, cancer vaccines, and inflammatory diseases. Pipeline includes CLM-022 inflammasome inhibitor and tolerogenic dendritic cell therapies.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

MedPacto competitors and assessment

Company assessment

Direct peers

  • MacroGenics: US clinical-stage immuno-oncology biotech developing antibody-based therapeutics including combinations with checkpoint inhibitors. Comparable business model as a clinical-stage IO platform company pursuing combination strategies with PD-1/PD-L1 agents.
  • Scholar Rock: US clinical-stage biotech focused on TGF-β superfamily biology (latent TGF-β activation), with lead asset apitegromab in neuromuscular disease. Directly comparable as a TGF-β platform company advancing targeted therapeutics into Phase 3.
  • Genexine: Korean clinical-stage biotechnology company developing immuno-oncology and immunology therapeutics with a comparable size, public KOSDAQ listing, and strategic overlap in cancer combination therapies. Direct overlap in Korean biotech peer set and former employer of MedPacto's new CEO.
  • Genfit: French clinical-stage biopharmaceutical company focused on inflammatory and metabolic diseases, and current licensee of MedPacto's Celloram subsidiary's CLM-022 inflammasome inhibitor. Comparable as a clinical-stage partner with shared deal economics.

Emerging players

  • BeiGene: Global oncology company with broad immuno-oncology pipeline including checkpoint inhibitors used in combination trials. Comparable as a peer that validates the immuno-oncology combination strategy MedPacto is pursuing.
  • I-Mab Biopharma: Clinical-stage biotech developing immuno-oncology assets including bispecific antibodies and combinations. Comparable as an emerging player in the IO space pursuing global partnership opportunities with large pharma.
  • Innovent Biologics: Chinese clinical-stage and commercial biotech with strong PD-1 combination pipeline. Comparable as an Asian emerging player developing IO combination therapies and pursuing global pharmaceutical partnerships.

Regional players

  • Hanmi Pharmaceutical: Korean pharmaceutical innovator with multiple oncology and immunology pipeline assets. Comparable as a Korean regional player with similar pipeline strategies targeting global partnerships and out-licensing opportunities.
  • Yuhan Corporation: Major Korean pharmaceutical company with growing oncology and innovative drug pipeline. Comparable as a domestic Korean partner with capacity to in-license or collaborate on MedPacto's pipeline assets in the Korean market.

Broad incumbents

  • Eli Lilly (galunisertib historical): Large pharmaceutical company that historically developed galunisertib, a competing TGF-β receptor I inhibitor in oncology. Comparable as a broad incumbent whose TGF-β clinical outcomes inform the validation and competitive context for MedPacto's Vactosertib.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

MedPacto social profiles

Digital presence

MedPacto financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MedPacto leadership team

Management profile

Number of profiles

Profiles14 records

MedPacto subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

MedPacto funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MedPacto M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MedPacto

What does MedPacto do?

MedPacto is a clinical-stage biopharmaceutical company developing biomarker-based first-in-class therapeutics centered on TGF-β signaling inhibition for cancer and inflammatory diseases. Its lead asset, oral Vactosertib, is being advanced in monotherapy and combination regimens across multiple cancer types, supplemented by pipeline candidates MP010, MP2021, MA-B2, and MO-B2 companion diagnostic. The company generates near-term revenue through licensing, co-development milestones, and royalties, and plans future commercialization via partnerships with global pharmaceutical companies.

Is MedPacto a public or private company?

MedPacto is a public company. It is classified as public and is currently operating.

When was MedPacto founded?

MedPacto was founded in 2013. It employs 11 to 50 people.

Where is MedPacto based?

MedPacto is headquartered in Seoul, South Korea, in the Asia region.

How does MedPacto make money?

One revenue line is on record: drug Development and Commercialization.

Who are MedPacto's main competitors?

Direct peers on record are MacroGenics, Scholar Rock, Genexine and Genfit. Emerging players are BeiGene, I-Mab Biopharma and Innovent Biologics. Regional players are Hanmi Pharmaceutical and Yuhan Corporation. Eli Lilly (galunisertib historical) is listed as a broad incumbent.

Does MedPacto have an API?

No public API is recorded for MedPacto.

What industry is MedPacto in?

MedPacto's product category is Clinical-stage Biopharmaceuticals (Oncology). Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StWe're Hopeful That MedPacto (KOSDAQ:235980) Will Use Its Cash WiselyMedPacto has a cash runway of about 2.9 years as of June 2026, with ₩35b in cash and ₩12b annual cash burn. Its burn rate rose 12% year-over-year, and raising another year's cash would dilute shareholders by about 12% of its ₩108b market cap.The future of tradingMedPacto Wins FDA Approval to Modify Phase 1/2 Vactosertib Trial in OsteosarcomaMedPacto received FDA clearance on October 19, 2026, to modify its Phase 1/2 trial of vactosertib monotherapy for osteosarcoma. The trial compares 200 mg and 300 mg twice-daily doses to identify the optimal dose, with the study scheduled to finish on February 29, 2028.FinancialContent Business PageScientists Turn COVID-19 Immune Memory into a Powerful New Ally Against CancerScientists from Celloram Inc., University Hospitals, and Case Western Reserve University have developed PROTEXI, a novel dendritic cell cancer vaccine platform that leverages pre-existing SARS-CoV-2 immune memory to amplify the body's ability to recognize and destroy tumors, with findings published in Nature Communications. In preclinical models of melanoma, breast cancer, and humanized mouse models, PROTEXI slowed tumor growth, improved survival, and transformed treatment-resistant tumors into more immune-responsive ones, particularly when combined with MedPacto's TGF-β inhibitor vactosertib or immune-checkpoint inhibitors. The team is advancing PROTEXI toward first-in-human clinical trials in patients with sarcoma, representing a potentially paradigm-shifting approach to cancer vaccine design.GlobeNewswireScientists Turn COVID-19 Immune Memory into a Powerful New Ally Against CancerScientists from Celloram Inc., University Hospitals, and Case Western Reserve University have developed PROTEXI, a dendritic cell cancer vaccine platform that leverages pre-existing SARS-CoV-2 immune memory to amplify antitumor immune responses, with findings published in Nature Communications on July 27, 2026. In multiple preclinical models of melanoma, breast cancer, and humanized mouse models, PROTEXI significantly reduced tumor burden, improved survival, and worked synergistically with MedPacto's TGF-β inhibitor vactosertib and anti-PD-1 checkpoint inhibitors. The research team is now advancing PROTEXI toward first-in-human clinical trials in patients with sarcoma.NateMedpacto, bone disease treatment drug 'MP2021' clinical application in Australia: Nate NewsMedpacto submitted a Phase 1 clinical trial plan for its drug candidate MP2021 to the Australian Human Research Ethics Committee (HREC), targeting the cell membrane protein TM4SF19 to treat bone diseases and inflammatory autoimmune disorders such as rheumatoid arthritis, osteoporosis, and bone metastasis. The company selected Australia to generate rapid, globally recognized clinical data and to access patients with rare bone diseases, as Australian clinical data is accepted by the FDA and EMA. Medpacto is also developing additional new modality programs targeting TM4SF19 and pursuing antibody-drug conjugate (ADC) preclinical research through a partnership with a major Japanese pharmaceutical company.NateMedPacto, osteoclast inhibitor 'MP2021' phase 1 application in Australia: Nate NewsMedPacto (stock code 235980) announced on July 15 that it has filed a Phase 1 clinical trial application with Australia's Human Research Ethics Committee (HREC) for its novel osteoclast formation inhibitor, MP2021. The trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity in healthy adult subjects using a randomized, single-blind, placebo-controlled, single ascending dose design enrolling up to 32 participants across up to four dose groups (1.5, 3, 6 mg/kg, with a potential 9 mg/kg group). The clinical trial will be conducted at Nucleus Network in Sydney, with Phase 1 expected to begin in Q4 2025 and complete by Q4 2028.openPR.comUrothelial Carcinoma Clinical Trial Pipeline Expands as 40+ Pharma Companies Progress 50+ Novel Therapies Toward Market Entry, Finds DelveInsight | Janssen Research and Development, MedPactoDelveInsight released its 'Urothelial Carcinoma - Pipeline Insight, 2026' report documenting over 40 pharmaceutical companies developing more than 50 pipeline therapies for urothelial carcinoma treatment. The most advanced candidate is Cetrelimab by Janssen Research and Development, currently in Phase III clinical development, while Pemazyre (pemigatinib) by Incyte Corporation is also being evaluated for this indication.PR NewswireChime Biologics and Korean Listed Company MedPacto Form Strategic Partnership to Accelerate Global Biologics Development and ManufacturingChime Biologics, a leading global CDMO, announced a strategic collaboration with MedPacto, a South Korean KOSDAQ-listed cancer therapeutics company, to advance the CMC process development for MedPacto's preclinical drug candidates and enable streamlined clinical manufacturing for IND submissions. Under the agreement, Chime Biologics will leverage its expertise in biologics development to support MedPacto's expansion into major global markets. Chime Biologics is simultaneously expanding its manufacturing capacity to 100,000 liters as part of its strategy to establish a stronger presence in the South Korean biopharmaceutical market.KBRMedPacto, MSD to start investigator-initiated clinical trials for colon cancer drugMedPacto, UCSF, and MSD signed an agreement to conduct investigator-initiated clinical trials for colon cancer therapies. The trials will test Vactosertib combined with Keytruda as neoadjuvant and adjuvant therapy, with MedPacto providing Vactosertib and MSD supplying Keytruda. MedPacto expects adjuvant therapy authorization if the study shows significant outcomes.The Korea HeraldKorean pharmas present latest findings at tumor forumKorean pharma companies Samsung Bioepis, Celltrion, Genexine, and MedPacto presented oncology pipeline findings at the virtual ASCO20 conference. Samsung Bioepis reported its trastuzumab biosimilar Ontruzant showed better event-free survival (83.4% vs 80.7%) and overall survival (94.4% vs 89.6%) versus Herceptin. Celltrion's Herzuma showed 95.3% tumor shrinkage in a trial, and MedPacto's Vactosertib showed no concerning toxicity.